Biophan Receives 'Buy' Rating from Leading European Analyst MIDAS Research Wednesday August 31, 9:05 am ET Research Report Notes Biomedical Company for Innovative Nanotechnology-Based Solutions and Receives $4.20 Price Target
ROCHESTER, N.Y.--(BUSINESS WIRE)--Aug. 31, 2005--Biophan Technologies, Inc. (OTCBB: BIPH - News), a developer of next-generation biomedical technology, has received an unqualified "buy" rating in an independent, third-party research report written by a leading German analyst, MIDAS Research GmbH.
IP: Logged |